GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » Interest and Commission Paid

Arena Pharmaceuticals (FRA:RN3N) Interest and Commission Paid


View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Interest and Commission Paid?

Interest and Commission Paid only applicable to companies reporting Cash Flow from Operations in direct method.


Arena Pharmaceuticals (FRA:RN3N) Business Description

Traded in Other Exchanges
N/A
Address
136 Heber Avenue, Suite 204, Park City, UT, USA, 84060
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.